AF
PCVX icon

Allworth Financial’s Vaxcyte PCVX Stock Holding History

Allworth Financial’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.7K Sell
1,285
-152
-11% -$8.26K ﹤0.01% 2155
2026
Q1 		$83.5K Buy
1,437
+180
+14% +$9.77K ﹤0.01% 1954
2025
Q4 		$58K Buy
1,257
+35
+3% +$1.56K ﹤0.01% 2099
2025
Q3 		$44K Buy
1,222
+731
+149% +$24.2K ﹤0.01% 2186
2025
Q2 		$16K Buy
491
+419
+582% +$13.7K ﹤0.01% 2652
2025
Q1 		$2.48K Sell
72
-72
-50% -$5.76K ﹤0.01% 3118
2024
Q4 		$12.4K Buy
144
+39
+37% +$3.87K ﹤0.01% 2349
2024
Q3 		$12K Buy
105
+29
+38% +$2.61K ﹤0.01% 2188
2024
Q2 		$6.2K Buy
76
+45
+145% +$3.06K ﹤0.01% 2415
2024
Q1 		$2.12K Buy
31
+4
+15% +$277 ﹤0.01% 2783
2023
Q4 		$1.7K Sell
27
-2
-7% -$104 ﹤0.01% 2746
2023
Q3 		$1.48K Buy
+29
New +$1.43K ﹤0.01% 2680
2023
Q1 		– Sell
-31
Closed -$1.49K – 3268
2022
Q4 		$1.49K Buy
+31
New +$1.22K ﹤0.01% 2342

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Allworth Financial's PCVX Position: Q2 2026 in Review

Allworth Financial reduced its Vaxcyte (PCVX) stake by 11% in Q2 2026, selling an estimated $8.26K and leaving 1,285 shares worth $74.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2155.

Allworth Financial first reported a position in PCVX in Q4 2022 and has held it in 13 quarters since. The position peaked at $83.5K in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Allworth Financial held 1,285 shares of Vaxcyte worth $74.7K as of Q2 2026.
  • Allworth Financial sold 152 Vaxcyte shares in Q2 2026, an estimated $8.26K.
  • Vaxcyte made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #2155 holding.
  • Allworth Financial first reported a position in Vaxcyte in Q4 2022 and has held it in 13 quarters since.
  • Allworth Financial's Vaxcyte position peaked at $83.5K in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.